Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-627 in breast cancer patients receiving myelotoxic chemotherapy
NCT02521441Phase 2Completed
- Sponsor
- Evive Biotech
- Start
- Jul 2014
- Primary completion
- Sep 2015
- Countries
- 1
01
Overview
A Phase 2 trial of efbemalenograstim alfa in neutropenia, sponsored by Evive Biotech. Started Jul 2014; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02521441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521441.